| 31712133 |
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
Noe, J,
Lovejoy, A,
Ou, SI,
Yaung, SJ,
Bordogna, W,
Klass, DM,
Cummings, CA,
Shaw, AT
|
J Thorac Oncol |
2020 |
| 25393798 |
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib
Toyokawa, G,
Hirai, F,
Inamasu, E,
Yoshida, T,
Nosaki, K,
Takenaka, T,
Yamaguchi, M,
Seto, T,
Takenoyama, M,
Ichinose, Y
|
J Thorac Oncol |
2014 |
| 21948233 |
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Heuckmann, JM,
Hölzel, M,
Sos, ML,
Heynck, S,
Balke-Want, H,
Koker, M,
Peifer, M,
Weiss, J,
Lovly, CM,
Grütter, C,
Rauh, D,
Pao, W,
Thomas, RK
|
Clin. Cancer Res. |
2011 |
| 22277784 |
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
Katayama, R,
Shaw, AT,
Khan, TM,
Mino-Kenudson, M,
Solomon, BJ,
Halmos, B,
Jessop, NA,
Wain, JC,
Yeo, AT,
Benes, C,
Drew, L,
Saeh, JC,
Crosby, K,
Sequist, LV,
Iafrate, AJ,
Engelman, JA
|
Sci Transl Med |
2012 |
| 30089600 |
Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient
Ai, X,
Niu, X,
Chang, L,
Chen, R,
Ou, SI,
Lu, S
|
Lung Cancer |
2018 |
| 27045755 |
Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing
Saber, A,
van der Wekken, AJ,
Kok, K,
Terpstra, MM,
Bosman, LJ,
Mastik, MF,
Timens, W,
Schuuring, E,
Hiltermann, TJ,
Groen, HJ,
van den Berg, A
|
PLoS One |
2016 |
| 20979473 |
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
Choi, YL,
Soda, M,
Yamashita, Y,
Ueno, T,
Takashima, J,
Nakajima, T,
Yatabe, Y,
Takeuchi, K,
Hamada, T,
Haruta, H,
Ishikawa, Y,
Kimura, H,
Mitsudomi, T,
Tanio, Y,
Mano, H,
ALK Lung Cancer Study Group, -
|
N. Engl. J. Med. |
2010 |
| 24675041 |
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
Friboulet, L,
Li, N,
Katayama, R,
Lee, CC,
Gainor, JF,
Crystal, AS,
Michellys, PY,
Awad, MM,
Yanagitani, N,
Kim, S,
Pferdekamper, AC,
Li, J,
Kasibhatla, S,
Sun, F,
Sun, X,
Hua, S,
McNamara, P,
Mahmood, S,
Lockerman, EL,
Fujita, N,
Nishio, M,
Harris, JL,
Shaw, AT,
Engelman, JA
|
Cancer Discov |
2014 |
| 21030459 |
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
Sasaki, T,
Okuda, K,
Zheng, W,
Butrynski, J,
Capelletti, M,
Wang, L,
Gray, NS,
Wilner, K,
Christensen, JG,
Demetri, G,
Shapiro, GI,
Rodig, SJ,
Eck, MJ,
Jänne, PA
|
Cancer Res |
2010 |
| 27432227 |
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Gainor, JF,
Dardaei, L,
Yoda, S,
Friboulet, L,
Leshchiner, I,
Katayama, R,
Dagogo-Jack, I,
Gadgeel, S,
Schultz, K,
Singh, M,
Chin, E,
Parks, M,
Lee, D,
DiCecca, RH,
Lockerman, E,
Huynh, T,
Logan, J,
Ritterhouse, LL,
Le, LP,
Muniappan, A,
Digumarthy, S,
Channick, C,
Keyes, C,
Getz, G,
Dias-Santagata, D,
Heist, RS,
Lennerz, J,
Sequist, LV,
Benes, CH,
Iafrate, AJ,
Mino-Kenudson, M,
Engelman, JA,
Shaw, AT
|
Cancer Discov |
2016 |
| 23434628 |
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment
Huang, D,
Kim, DW,
Kotsakis, A,
Deng, S,
Lira, P,
Ho, SN,
Lee, NV,
Vizcarra, P,
Cao, JQ,
Christensen, JG,
Kim, TM,
Sun, JM,
Ahn, JS,
Ahn, MJ,
Park, K,
Mao, M
|
Genomics |
2013 |
| 21791641 |
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
Sasaki, T,
Koivunen, J,
Ogino, A,
Yanagita, M,
Nikiforow, S,
Zheng, W,
Lathan, C,
Marcoux, JP,
Du, J,
Okuda, K,
Capelletti, M,
Shimamura, T,
Ercan, D,
Stumpfova, M,
Xiao, Y,
Weremowicz, S,
Butaney, M,
Heon, S,
Wilner, K,
Christensen, JG,
Eck, MJ,
Wong, KK,
Lindeman, N,
Gray, NS,
Rodig, SJ,
Jänne, PA
|
Cancer Res. |
2011 |
| 23239810 |
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
Ceccon, M,
Mologni, L,
Bisson, W,
Scapozza, L,
Gambacorti-Passerini, C
|
Mol. Cancer Res. |
2013 |
| 30675302 |
ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report
Xu, X,
Li, H,
Peng, K,
Yu, Y,
Chen, L,
Fang, Y,
Sun, Y,
Hou, Y,
Liu, T
|
Oncol Lett |
2019 |
| 21502504 |
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Katayama, R,
Khan, TM,
Benes, C,
Lifshits, E,
Ebi, H,
Rivera, VM,
Shakespeare, WC,
Iafrate, AJ,
Engelman, JA,
Shaw, AT
|
Proc. Natl. Acad. Sci. U.S.A. |
2011 |
| 22235099 |
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
Doebele, RC,
Pilling, AB,
Aisner, DL,
Kutateladze, TG,
Le, AT,
Weickhardt, AJ,
Kondo, KL,
Linderman, DJ,
Heasley, LE,
Franklin, WA,
Varella-Garcia, M,
Camidge, DR
|
Clin. Cancer Res. |
2012 |
| 24736079 |
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib
Ignatius Ou, SH,
Azada, M,
Hsiang, DJ,
Herman, JM,
Kain, TS,
Siwak-Tapp, C,
Casey, C,
He, J,
Ali, SM,
Klempner, SJ,
Miller, VA
|
J Thorac Oncol |
2014 |
| 23344087 |
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer
Kim, S,
Kim, TM,
Kim, DW,
Go, H,
Keam, B,
Lee, SH,
Ku, JL,
Chung, DH,
Heo, DS
|
J Thorac Oncol |
2013 |
| 31749991 |
Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review
Kougioumtzi, A,
Ntellas, P,
Papadopoulou, E,
Nasioulas, G,
Kampletsas, E,
Pentheroudakis, G
|
ESMO Open |
2019 |
